GeneOne Life Science Balance Sheet Health
Financial Health criteria checks 4/6
GeneOne Life Science has a total shareholder equity of ₩105.4B and total debt of ₩13.7B, which brings its debt-to-equity ratio to 13%. Its total assets and total liabilities are ₩150.6B and ₩45.2B respectively.
Key information
13.0%
Debt to equity ratio
₩13.67b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩4.50b |
| Equity | ₩105.44b |
| Total liabilities | ₩45.17b |
| Total assets | ₩150.60b |
Recent financial health updates
Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31
Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?
Mar 20Recent updates
The Market Doesn't Like What It Sees From GeneOne Life Science, Inc.'s (KRX:011000) Revenues Yet As Shares Tumble 39%
Sep 09Is GeneOne Life Science (KRX:011000) Using Too Much Debt?
Aug 31Why Investors Shouldn't Be Surprised By GeneOne Life Science, Inc.'s (KRX:011000) Low P/S
Jul 26Is GeneOne Life Science (KRX:011000) Using Debt In A Risky Way?
Mar 20GeneOne Life Science (KRX:011000) Has Rewarded Shareholders With An Exceptional 855% Total Return On Their Investment
Jan 10
Financial Position Analysis
Short Term Liabilities: A011000's short term assets (₩30.3B) exceed its short term liabilities (₩24.2B).
Long Term Liabilities: A011000's short term assets (₩30.3B) exceed its long term liabilities (₩21.0B).
Debt to Equity History and Analysis
Debt Level: A011000's net debt to equity ratio (8.7%) is considered satisfactory.
Reducing Debt: A011000's debt to equity ratio has reduced from 52% to 13% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A011000 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A011000 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25% each year